{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:26:05Z","timestamp":1769603165065,"version":"3.49.0"},"reference-count":15,"publisher":"Walter de Gruyter GmbH","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_jpem-2019-0393_s_999_w2aab3b7c40b1b6b1aab1c16b1Aa\">\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Recently, urinary excretion of the tetrasaccharide 6-\u03b1-D-glucopyranosyl-maltotriose (Glc4) has been proposed as a marker for the diagnosis and monitoring of Pompe disease (PD). We aimed to determine the reference intervals and reliable decision-making levels of urine tetrasaccharide concentrations for the diagnosis of infantile- and late-onset Pompe patients in the Turkish population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2019-0393_s_998_w2aab3b7c40b1b6b1aab1c16b2Aa\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this study, nine patients with PD (five of them with late-onset PD [LOPD]) and 226 healthy individuals (aged 0\u201364 years) were included. Urine Glc4 concentrations were determined using the ultra-high-performance liquid chromatography (UHPLC) tandem mass spectrometry (MS\/MS) method.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2019-0393_s_997_w2aab3b7c40b1b6b1aab1c16b3Aa\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Our data showed that the urine tetrasaccharide levels decreased with age in healthy individuals (p\u2009&lt;\u20090.001, r\u2009=\u2009\u22120.256). It was higher especially during the first year of life compared to that in the elder subjects. The tetrasaccharide level of Pompe patients was higher compared to that of healthy controls of the same age: 99\u2009\u00b1\u200968 mmol\/mol creatinine for infantile onset vs. 4.0\u2009\u00b1\u20093.0 mmol\/mol creatinine for healthy controls of the same age group and 12.1\u2009\u00b1\u200917.4 mmol\/mol creatinine for late onset vs. 1.7\u00b11.2 mmol\/mol creatinine for healthy controls of the same age group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2019-0393_s_996_w2aab3b7c40b1b6b1aab1c16b4Aa\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The results of this study showed that the reference intervals of tetrasaccharide in urine changed over time; therefore, it is critically important to define age-based decision levels for the diagnosis of LOPD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/jpem-2019-0393","type":"journal-article","created":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T09:03:21Z","timestamp":1582016601000},"page":"391-395","source":"Crossref","is-referenced-by-count":4,"title":["The decision-making levels of urine tetrasaccharide for the diagnosis of Pompe disease in the Turkish population"],"prefix":"10.1515","volume":"33","author":[{"given":"Erhan","family":"Canbay","sequence":"first","affiliation":[{"name":"Ege University , Faculty of Medicine, Department of Medical Biochemistry , Izmir , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melisa","family":"Vural","sequence":"additional","affiliation":[{"name":"Ege University , Faculty of Medicine, Department of Medical Biochemistry , Izmir , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sema","family":"Kalkan U\u00e7ar","sequence":"additional","affiliation":[{"name":"Ege University , Faculty of Medicine, Department of Pediatric Metabolism , Izmir , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ebru Demirel","family":"Sezer","sequence":"additional","affiliation":[{"name":"Ege University , Faculty of Medicine, Department of Medical Biochemistry , Izmir , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hatice","family":"Karasoy","sequence":"additional","affiliation":[{"name":"Ege University , Faculty of Medicine, Department of Neurology , Izmir , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ay\u015fe Nur","family":"Y\u00fcceyar","sequence":"additional","affiliation":[{"name":"Ege University , Faculty of Medicine, Department of Neurology , Izmir , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmut","family":"\u00c7oker","sequence":"additional","affiliation":[{"name":"Ege University , Faculty of Medicine, Department of Pediatric Metabolism , Izmir , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eser Yildirim","family":"S\u00f6zmen","sequence":"additional","affiliation":[{"name":"Ege University , Faculty of Medicine, Department of Medical Biochemistry , Izmir , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2020,2,18]]},"reference":[{"key":"2023040101053369686_j_jpem-2019-0393_ref_001_w2aab3b7c40b1b6b1ab2b1b1Aa","doi-asserted-by":"crossref","unstructured":"Kemper AR, Hwu WL, Lloyd-Puryear M, Kishnani PS. Newborn screening for Pompe disease: synthesis of the evidence and development of screening recommendations. Pediatrics 2007;120:1327\u201334.","DOI":"10.1542\/peds.2007-0388"},{"key":"2023040101053369686_j_jpem-2019-0393_ref_002_w2aab3b7c40b1b6b1ab2b1b2Aa","doi-asserted-by":"crossref","unstructured":"ACMG Work Group on Management of Pompe Disease, Kishnani PS, Steiner RD, Bali D, Berger K, et al. Pompe disease diagnosis and management guideline. Genet Med 2006;8:267\u201388.","DOI":"10.1097\/01.gim.0000218152.87434.f3"},{"key":"2023040101053369686_j_jpem-2019-0393_ref_003_w2aab3b7c40b1b6b1ab2b1b3Aa","doi-asserted-by":"crossref","unstructured":"Spada M, Pagliardini M, Ricci F, Biamino E, Mongini T, et al. Early higher dosage of alglucosidase alpha in classic Pompe disease. J Pediatr Endocrinol Metab 2018;31:1343\u20137.","DOI":"10.1515\/jpem-2018-0336"},{"key":"2023040101053369686_j_jpem-2019-0393_ref_004_w2aab3b7c40b1b6b1ab2b1b4Aa","doi-asserted-by":"crossref","unstructured":"Chien YH, Goldstein JL, Hwu WL, Smith PB, Lee NC, et al. Baseline urinary glucose tetrasaccharide concentrations in patients with infantile- and late-onset Pompe disease identified by newborn screening. JIMD Rep 2015;19:67\u201373.","DOI":"10.1007\/8904_2014_366"},{"key":"2023040101053369686_j_jpem-2019-0393_ref_005_w2aab3b7c40b1b6b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"Kumlien J, Chester MA, Lindberg BS, Pizzo P, Zopf D, et al. Urinary excretion of a glucose-containing tetrasaccharide. A parameter for increased degradation of glycogen. Clin Chim Acta 1988;176:39\u201348.","DOI":"10.1016\/0009-8981(88)90172-6"},{"key":"2023040101053369686_j_jpem-2019-0393_ref_006_w2aab3b7c40b1b6b1ab2b1b6Aa","doi-asserted-by":"crossref","unstructured":"Young SP, Zhang H, Corzo D, Thurberg BL, Bali D, et al. Long-term monitoring of patients with infantile-onset Pompe disease on enzyme replacement therapy using a urinary glucose tetrasaccharide biomarker. Genet Med 2009;11:536\u201341.","DOI":"10.1097\/GIM.0b013e3181a87867"},{"key":"2023040101053369686_j_jpem-2019-0393_ref_007_w2aab3b7c40b1b6b1ab2b1b7Aa","doi-asserted-by":"crossref","unstructured":"Young SP, Piraud M, Goldstein JL, Zhang H, Rehder C, et al. Assessing disease severity in Pompe disease: the roles of a urinary glucose tetrasaccharide biomarker and imaging techniques. Am J Med Genet C Semin Med Genet 2012;160C:50\u20138.","DOI":"10.1002\/ajmg.c.31320"},{"key":"2023040101053369686_j_jpem-2019-0393_ref_008_w2aab3b7c40b1b6b1ab2b1b8Aa","doi-asserted-by":"crossref","unstructured":"Young SP, Stevens RD, An Y, Chen Y-T, Millington DS. Analysis of a glucose tetrasaccharide elevated in Pompe disease by stable isotope dilution\u2013electrospray ionization tandem mass spectrometry. Anal Biochem 2003;316:175\u201380.","DOI":"10.1016\/S0003-2697(03)00056-3"},{"key":"2023040101053369686_j_jpem-2019-0393_ref_009_w2aab3b7c40b1b6b1ab2b1b9Aa","doi-asserted-by":"crossref","unstructured":"Ann Y, Young SP, Kishnani PS, Millington DS, Wtano AA, et al. Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease. Mol Genet Metab 2005;85:247\u201354.","DOI":"10.1016\/j.ymgme.2005.03.010"},{"key":"2023040101053369686_j_jpem-2019-0393_ref_010_w2aab3b7c40b1b6b1ab2b1c10Aa","doi-asserted-by":"crossref","unstructured":"Blom W, Luteyn JC, Kelholt-Dijkman HH, Huijmans JG, LoonenMC. Thin-layer chromatography of oligosaccharides in urine as a rapid indication for the diagnosis of lysosomal acid maltase deficiency (Pompe\u2019s disease). Clin Chim Acta 1983;134:221\u20137.","DOI":"10.1016\/0009-8981(83)90200-0"},{"key":"2023040101053369686_j_jpem-2019-0393_ref_011_w2aab3b7c40b1b6b1ab2b1c11Aa","doi-asserted-by":"crossref","unstructured":"An Y, Young SP, Hillman SL, Van Hove LK, Chen YT, et al. Liquid chromatographic assay for a glucose tetrasaccharide, a putative biomarker for the diagnosis of Pompe disease. Anal Biochem 2000;287:136\u201343.","DOI":"10.1006\/abio.2000.4838"},{"key":"2023040101053369686_j_jpem-2019-0393_ref_012_w2aab3b7c40b1b6b1ab2b1c12Aa","doi-asserted-by":"crossref","unstructured":"Sluiter W, van den Bosch JC, Goudriaan DA, van Gelder CM, de Vries JM, et al. Rapid ultraperformance liquid chromatography\u2013tandem mass spectrometry assay for a characteristic glycogen-derived tetrasaccharide in Pompe disease and other glycogen storage diseases. Clin Chem 2012;58:1139\u201347.","DOI":"10.1373\/clinchem.2011.178319"},{"key":"2023040101053369686_j_jpem-2019-0393_ref_013_w2aab3b7c40b1b6b1ab2b1c13Aa","unstructured":"National Committee for Clinical Laboratory Standards. How to define and determine reference intervals in the clinical laboratory: approved guideline. 2001, NCCLS document C28-A and C28-A2, Villanova, PA, NCCLS."},{"key":"2023040101053369686_j_jpem-2019-0393_ref_014_w2aab3b7c40b1b6b1ab2b1c14Aa","doi-asserted-by":"crossref","unstructured":"Horn PS, Pesce AJ. Reference intervals: an update. Clin Chim Acta 2003;334:5\u201323.","DOI":"10.1016\/S0009-8981(03)00133-5"},{"key":"2023040101053369686_j_jpem-2019-0393_ref_015_w2aab3b7c40b1b6b1ab2b1c15Aa","doi-asserted-by":"crossref","unstructured":"Aldemir O, Ergun P, G\u00fcne\u015f S, K\u00f6ro\u011flu OA, Yalaz M, et al. Reference intervals of \u03b1-glycosidase, \u03b2-glycosidase and \u03b1-galactosidase \u0131n dr\u0131ed blood spot of newborn \u0131n a Turkish population. Eur J Pediatrics 2013;172:1221\u20137.","DOI":"10.1007\/s00431-013-2026-3"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/jpem\/33\/3\/article-p391.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2019-0393\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2019-0393\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T17:59:54Z","timestamp":1680371994000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2019-0393\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,18]]},"references-count":15,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,2,17]]},"published-print":{"date-parts":[[2020,3,26]]}},"alternative-id":["10.1515\/jpem-2019-0393"],"URL":"https:\/\/doi.org\/10.1515\/jpem-2019-0393","relation":{},"ISSN":["2191-0251","0334-018X"],"issn-type":[{"value":"2191-0251","type":"electronic"},{"value":"0334-018X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2,18]]}}}